

The quick ratio is the one that bears the most weight among these three. In this scenario, the quick ratio is 1.43, the current ratio is 1.27, and the debt-to-equity ratio is 1.30. Gilead Sciences hit an all-time low of $57.17 and an all-time high of $74.12 throughout their 52-week trading range. When the market opened on Friday, the GILD’s share price was $64.95 per share. 78.58% of the company’s shares are owned by institutional investors and hedge funds, making them the majority of shareholders. These shares were acquired over the most recent fiscal quarter. After investing in 56,988 shares during the most recent quarter, Stifel Financial Corp now holds 1,784,036 shares of the biopharmaceutical company’s stock, with a market value of $129,538,000. acquired a 3.3% stake in Gilead Sciences, bringing its total ownership to 68.7%. During the final three months of the fiscal year, Stifel Financial Corp. Additional investment for $6,819,000 was made in the company Gilead Sciences by Schonfeld Strategic Advisors LLC during the final three months of 2018. In addition, Gilead Sciences received an investment of 344 thousand dollars from Laidlaw Wealth Management LLC during the final three months of 2018. This gives the company a combined value of $855,000. now has 11,779 shares of stock in the biopharmaceutical business after purchasing an additional 4,511 shares.

saw a 62.1% increase in the percentage of its holdings invested in Gilead Sciences. During the last three months of 2018, the investment portfolio managed by Laurel Wealth Advisors, Inc. After the most recent fiscal quarter, Mackenzie Financial Corp had acquired 530,234 shares of the biopharmaceutical company’s stock, which had a market value of $38,500,000 at that time. Mackenzie Financial Corporation increased its stake in Gilead Sciences by 4.5% during the most recent reporting period by purchasing additional shares. In a report published on Monday, August 15, TheStreet moved Gilead Sciences’ rating from “c+” to “b-” after evaluating the company.ĭuring the previous few months, several hedge funds and other types of institutional investors have modified their strategies to invest in the company. In addition, the company’s rating for Gilead Sciences went from “neutral” to “overweight” after the adjustment. raised their price target for Gilead Sciences from $72.00 to $80.00, which was previously set at $72.00. In a research report released on Tuesday, JPMorgan Chase & Co. The price objective that the company had established for Gilead Sciences was increased from $71.00 to $76.00 within the report’s scope. In a research report on Gilead Sciences published on Thursday, September 15, Truist Financial recommended that investors “hold” their current position. In a research report released on September 12, Piper Sandler raised their price target on Gilead Sciences from $74.00 to $79.00. SVB Leerink reaffirmed its recommendation for investors to “market perform” on shares of Gilead Sciences in a research note published on September 15. Recent years have seen an uptick in the number of investigations and studies focusing on GILD. The average forecast of market analysts who have covered the stock in the preceding year projects that in one year, the share price will be $74.33, with some predicting that it will exceed that.ĭeposit $100 and get a $110 to trade stocks In addition, the stock has received six recommendations from investment analysts to buy it, eight recommendations to keep it in one’s portfolio, and one recommendation to sell it. (NASDAQ: GILD) have assigned the company a “Hold” rating as their recommendation for the average course of action regarding the company’s stock. According to, most of the 19 rating agencies that cover Gilead Sciences, Inc.
